The Patent Finder

Halozyme, Inc.

48 patents currently held · Updated Nov 15, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

6
Ending by 2030
Sep 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Sep 8 to 15, 2027 · next Sep 8
  • 1 fee due Oct 9, 2027
    The maintenance fee for PH20 Polypeptide Variants, Formulations and Uses Thereof (US 11,952,600) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
  • 1 fee due Nov 10, 2027
    The maintenance fee for Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia (US 9,333,244) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 17, 2026
  • 1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,767,429Soluble Hyaluronidase Glycoprotein (SHASEGP), Process for Preparing the Same, Uses and Pharmaceutical Compositions Comprising Thereof
In force
 · High confidence
In forceHigh confidence
US 7,871,607Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
In force
 · Medium confidence
In forceMedium confidence
US 8,187,855Large-Scale Production of Soluble Hyaluronidase
In force
 · High confidence
In forceHigh confidence
US 8,343,487Large-Scale Production of Soluble Hyaluronidase
In force
 · High confidence
In forceHigh confidence
US 9,775,889Methods of Treatment of Cellulite
In force
 · Medium confidence
In forceMedium confidence
US 9,833,498Methods of Treatment of Collagen-Mediated Diseases and Conditions
In force
 · Medium confidence
In forceMedium confidence
US 9,284,543Neutral Active Soluble Truncated PH20 Polypeptides and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,265,410Adverse Side-Effects Associated with Administration of an Anti-Hyaluronan Agent and Methods for Ameliorating or Preventing the Side-Effects
In force
 · High confidence
In forceHigh confidence
US 8,927,249Extended Soluble PH20 Polypeptides and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,018,298PH20 Polypeptide Variants, Formulations and Uses Thereof
In force
 · Low confidence
In forceLow confidence
10 of 48 patents shown.
Pro members see all 48.
Pro members: see all 48 patents
Also on record, not counted in the 48: 3 patents in force now held by others · 16 lapsed for an unpaid fee · 22 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

14 pending · 14 abandoned · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited